313 related articles for article (PubMed ID: 31925868)
21. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
22. An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data.
Kunyu L; Shuping S; Chang S; Yiyue C; Qinyu X; Ting Z; Bin W
J Clin Pharmacol; 2024 Apr; 64(4):478-489. PubMed ID: 38041205
[TBL] [Abstract][Full Text] [Related]
23. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
24. Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature.
Liu X; Zhao X; He Y; Tang Y; Yan XL; Zhao B; Dai Y
Expert Opin Drug Saf; 2022 Oct; 21(10):1329-1336. PubMed ID: 35315301
[TBL] [Abstract][Full Text] [Related]
25. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
26. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
27. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
28. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
[TBL] [Abstract][Full Text] [Related]
29. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
Jiang JJ; Zhao B; Li J
J Clin Pharm Ther; 2022 Oct; 47(10):1556-1562. PubMed ID: 35644838
[TBL] [Abstract][Full Text] [Related]
30. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
31. Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy.
Dixit S; Selva-Nayagam P; Hamann I; Fischer G
J Low Genit Tract Dis; 2015 Jan; 19(1):e6-9. PubMed ID: 24769650
[TBL] [Abstract][Full Text] [Related]
32. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
33. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
34. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
35. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
36. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.
Khoshnam-Rad N; Gheymati A; Jahangard-Rafsanjani Z
Anticancer Drugs; 2022 Jan; 33(1):e1-e8. PubMed ID: 34282745
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.
Pan C; Cao M; Yan C; Ou X; Zhang X; Xu W; Xu Y; Cui X
Expert Opin Drug Saf; 2023; 22(6):469-476. PubMed ID: 36794347
[TBL] [Abstract][Full Text] [Related]
39. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
[TBL] [Abstract][Full Text] [Related]
40. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
